Physician profile
Charles E Ruggeroli
NPI 1518907401
$7,812.10
in general payments reported to CMS, 2019-2025
34 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,155 · 2020: $707 · 2021: $665 · 2022: $774 · 2023: $479 · 2024: $548 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,058.45 | 2019-2025 | |
| Amgen INC. | $796.81 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $442.45 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $404.85 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.13 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $284.49 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals Lp | $248.35 | 2019-2025 | Farxiga |
| Abbott Laboratories | $234.62 | 2019-2025 | Merlin@Home, Jot Dx |
| Actelion Pharmaceuticals US, INC. | $175.00 | 2019-2024 | Opsumit, Uptravi |
| Cvrx, INC. | $166.27 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.21 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $149.10 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $136.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $132.27 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $115.30 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $111.51 | 2019-2022 | |
| Philips North America LLC | $102.69 | 2022 | |
| Boston Scientific Corporation | $95.94 | 2021-2025 | Watchman Flx, Varithena Administration Pack |
| Lexicon Pharmaceuticals, INC. | $87.18 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $86.51 | 2019 | |
| Astellas Pharma US INC | $79.92 | 2019-2022 | |
| Pfizer INC. | $57.18 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $55.72 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $55.40 | 2021 | |
| Irhythm Technologies, INC. | $49.48 | 2021-2024 | Zio Monitor, Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $46.58 | 2025 | Amvuttra |
| Portola Pharmaceuticals, LLC | $36.73 | 2019-2020 | |
| Medtronic Vascular, INC. | $32.25 | 2019-2020 | |
| Bridgebio Pharma, INC. | $30.44 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $23.04 | 2024 | Nexletol |
| Edwards Lifesciences Corporation | $17.74 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.60 | 2023 | Arcalyst |
| Amryt Pharma Holdings Ltd | $14.15 | 2021 | |
| Bardy Diagnostics, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ruggeroli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.